

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/OUTCOME/2020-21

Date: 30.06.2020

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

Company No.: 531146

Sub. : Outcome of Board Meeting.

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on March 31, 2020.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- a) Statement showing the Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2020 as **Annexure-A** and
- b) Audit Report on the Audited Financial Results (Standalone & Consolidated) as **Annexure-B**

Further Board of Directors at their meeting approved the following resolutions:

- c) Recommended a final dividend @ 5% on Equity Shares of Rs. 10/- each i.e. 50 paise per Equity Share for the Financial Year 2019-20.
- d) Appointment of M/s SPB & Co., Cost Accountants as Cost Auditor of the Company for the financial year 2020-21.
- e) Appointment of M/s Cheena & Associates as Internal Auditor of the Company for the financial year 2020-21.
- f) Appointment of M/s AMJ & Associates, Company Secretaries as Secretarial Auditor of the Company for the financial year 2020-21.
- g) Investor Release on the financial results is enclosed at **Annexure-C**

Please note that the reports of Auditors are with unmodified opinion with respect to the Audited Financial Results of the Company for the quarter/financial year ended March 31, 2020.

The meeting of the Board of Directors commenced on 1:30 pm and concluded at 3:20 p.m.

The Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2020, as approved by the Board, will also be available on the Company's website www.medicamen.com.


This is for your information and records.

Thanking You.

Yours faithfully,

For Medicamen Biotech Limited


Parul Choudhary
Company Secretary





MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Audited Standalone and Consolidated Financial Results for the quarter and Year ended on 31st March 2020

PART I

Rupees in Lacs (Except per Share data)

Particulars	Standalone					Consolidated				
	Quarter Ended			Year Ended		Quarter Ended			Year Ended	
	3 Months Ended 31.03.2020	Preceding 3 Months Ended 31.12.2019	Corresponding 3 Months Ended 31.03.2019	31.03.2020	31.03.2019	3 Months Ended 31.03.2020	Preceding 3 Months Ended 31.12.2019	Corresponding 3 Months Ended 31.03.2019	31.03.2020	31.03.2019
	Audited	Un-audited	Audited	Audited	Audited	Audited	Un-audited	Audited	Audited	Audited
1 Income from operations										
(a) Net Sales / Income from operations	1,536.33	3,533.49	2,408.25	11,734.23	12,260.45	2,352.47	3,533.49	2,408.25	12,550.38	12,260.45
(b) Other Income	106.64	45.07	7.12	190.86	365.87	109.67	45.07	7.12	193.88	365.87
(c) Total Revenue	1,642.97	3,578.56	2,415.37	11,925.09	12,626.32	2,462.14	3,578.56	2,415.37	12,744.26	12,626.32
2 Expenses										
a) Cost of Material Consumed	944.11	2,160.30	1,629.24	7,449.16	7,974.47	1,540.25	2,160.30	1,629.24	8,045.29	7,974.47
b) Purchase of Goods Traded					220.73	-	-	-	-	220.73
c) Changes in inventory of Finished Goods and Work in Progress	(232.99)	75.51	(184.09)	(153.25)	139.08	(232.99)	75.51	(184.09)	(153.25)	139.08
d) Employees Benefits Expenses	223.84	263.58	212.94	929.43	808.55	246.79	263.58	212.94	952.38	808.55
e) Finance Cost	-	19.10	20.33	56.85	93.77	-	19.10	20.33	56.85	93.77
f) Depreciation and Amortisation Expenses	66.68	63.91	59.24	249.92	221.40	66.68	63.91	59.24	249.92	221.40
g) Other expenses	440.46	490.33	312.12	1,732.59	1,416.04	502.92	490.33	312.12	1,795.05	1,416.04
Total Expenses	1,442.11	3,072.73	2,049.78	10,264.71	10,874.04	2,123.65	3,072.73	2,049.78	10,946.24	10,874.04
3 Profit/(Loss) before Exceptional Items & Tax (1 - 2)	200.86	505.83	365.59	1,660.39	1,752.28	338.49	505.83	365.59	1,798.02	1,752.28
4 Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-
5 Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	200.86	505.83	365.59	1,660.39	1,752.28	338.49	505.83	365.59	1,798.02	1,752.28
6 Tax Expenses										
Current Year	53.98	144.36	132.83	459.52	549.63	88.39	144.36	132.83	493.93	549.63
MAT Credit Entitlement										
Deferred Tax Liability	0.77	(6.47)	(7.69)	(25.03)	0.07	0.77	(6.47)	(7.69)	(25.03)	0.07
Total Tax Expense	54.75	137.89	125.14	434.49	549.70	89.16	137.89	125.14	468.90	549.70
7 Net Profit/Loss for the period from Continuing operation (5- 6)	146.11	367.94	240.45	1,225.89	1,202.58	249.33	367.94	240.45	1,329.12	1,202.58
8 Other Comprehensive Income										
Item that will not be reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-
9 Total Comprehensive Income net of Tax	146.11	367.94	240.45	1,225.89	1,202.58	249.33	367.94	240.45	1,329.12	1,202.58
10 Paid up equity share capital (Rs. 10/- per share)	1,221.66	1,221.66	1,170.00	1,221.66	1,170.00	1,221.66	1,221.66	1,170.00	1,221.66	1,170.00
11 Earning Per Share (Rs.)										
Basic	1.20	3.05	2.06	10.09	10.28	2.05	3.05	2.06	10.94	10.28
Diluted	1.20	3.05	2.06	10.09	10.28	2.05	3.05	2.06	10.94	10.28

NOTES :

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 30 June 2020.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share".
- Auditors Report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.
- During the Quarter-4, the order for Paracetamol, metronidazole, Azithromycin worth Rs. 18 Crores were cancelled due to the Ban imposed by Govt. Of India for Covid-19.
- Medicamen Biotech Limited has acquired controlling stake in Opal Pharmaceuticals Pty, Australia During the year. Opal Pharmaceuticals Pty, Australia, Figures have been consolidated at the end of the year.

For & on behalf of Board of Directors
Medicamen Biotech Limited

R. Bishnoi
(Rahul Bishnoi)
Chairman

Place : New Delhi
Date : 30.06.2020



MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019


CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Rupees In Lacs

STATEMENT OF ASSETS & LIABILITIES				
Particulars	Standalone		Consolidated	
	As at March 31, 2020 Audited	As at March 31, 2019 Audited	As at March 31, 2020 Audited	As at March 31, 2019 Audited
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	3,342.53	2,404.67	3,342.54	2,404.67
(b) Intangible assets	26.91	33.43	26.91	33.43
(c) Capital work-in-progress	4,049.57	1,475.83	4,049.57	1,475.83
(d) Investments	206.14	-	-	-
(e) Financial Assets : Loans and advances	62.73	58.03	62.73	58.03
(f) Other Non-current assets	233.41	70.45	233.41	70.45
Total Non-current Assets	7,921.29	4,042.41	7,715.16	4,042.41
2 Current assets				
(a) Inventories	1,695.75	1,526.03	1,695.75	1,526.03
(b) Financial Assets				
(i) Current investments	-	-	-	-
(ii) Trade receivables	4,393.01	4,337.09	4,995.82	4,337.09
(iii) Cash and Bank Balances	223.32	851.93	309.28	851.93
(iv) Loans and advances	857.69	1,054.05	857.69	1,054.05
(c) Other current assets	2,554.57	1,847.76	2,554.57	1,847.76
Total current Assets	9,724.34	9,616.86	10,413.11	9,616.86
Total Assets	17,645.63	13,659.27	18,128.27	13,659.27
B EQUITY AND LIABILITIES				
1 Equity				
(a) Equity share capital	1,221.66	1,170.00	1,221.66	1,170.00
(b) Other Equity	11,026.07	7,493.36	11,129.29	7,493.36
(c) Capital Reserve	-	-	(229.33)	-
Total Equity	12,247.73	8,663.36	12,121.62	8,663.36
LIBILITIES				
2 Non-current Liabilities				
(a) Financial Liabilities : Borrowings	235.85	2.09	235.85	2.09
(b) Provisions	106.03	98.02	106.03	98.02
(c) Deferred Tax liabilities (Net)	16.40	41.43	16.40	41.43
Total Non-current Liabilities	358.28	141.54	358.28	141.54
3 Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	761.57	1,161.33	761.57	1,161.33
(ii) Trade payables	3,195.71	3,056.98	3,738.11	3,056.98
(b) Other current liabilities	559.46	77.72	591.41	77.72
(c) Provisions	522.87	558.34	557.28	558.34
Total Equity and Liabilities	17,645.63	13,659.27	18,128.27	13,659.27

For & on behalf of Board of Directors
Medicamen Biotech Limited


(Rahul Bishnoi)
Chairman

Place : Delhi
Dated : 30.06.2020



MEDICAMEN BIOTECH LIMITED
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594

CASH FLOW STATEMENT FOR THE PERIOD 01.10.2019 TO 31.03.2020

Particulars	STANDALONE		CONSOLIDATED	
	Half Year ended 31st March, 2020	Half Year ended 30th Sep, 2019	Half Year ended 31st March, 2020	Half Year ended 30th Sep, 2019
CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit/(Loss) after tax from continuing operations	514.05	711.84	617.28	711.84
Non-cash adjustment to reconcile profit before tax to net cash flows				
Provision for Taxation	198.34	261.18	232.75	261.18
Depreciation/amortization on continuing operation	130.59	119.33	130.59	119.33
Loss/(profit) on sale of fixed assets	0.42	5.66	0.42	5.66
Interest expense	19.10	37.75	19.10	37.75
Interest income	(41.60)	9.64	(41.60)	9.64
Adjustment for Deferred Tax	(5.70)	(19.33)	(5.70)	(19.33)
Operating profit before working capital changes	815.21	1,126.07	952.84	1,126.07
MOVEMENTS IN WORKING CAPITAL:				
Increase/(decrease) in trade payables	(143.67)	282.40	398.73	282.40
Increase / (decrease) in long-term provisions	4.91	3.10	4.91	3.10
Increase / (decrease) in short-term provisions	(197.83)	(297.15)	(197.83)	(297.15)
Increase/(decrease) in other current liabilities	268.13	213.62	300.07	213.62
Decrease/(increase) in trade receivables	1,332.67	(1,388.59)	729.86	(1,388.59)
Decrease/(increase) in inventories	(414.50)	244.78	(414.50)	244.78
Decrease / (increase) in long-term loans and advances	(0.00)	(4.70)	(0.00)	(4.70)
Decrease / (increase) in short-term loans and advances	451.05	(254.70)	451.05	(254.70)
Decrease/(increase) in other current assets	(341.15)	69.34	(341.15)	69.34
Decrease/(increase) in other Non-current assets	(98.19)	(64.76)	(98.19)	(64.76)
Direct taxes paid (net of refunds)	(295.00)	(140.00)	(295.00)	(140.00)
Net cash flow from/ (used in) operating activities (A)	1,381.61	(210.59)	1,490.77	(210.59)
CASH FLOWS FROM INVESTING ACTIVITIES				
Purchase of fixed assets, including intangible assets and CWIP	(1,976.08)	(1,784.99)	(1,976.09)	(1,784.99)
Purchase of non-current investments	(206.14)	-	-	-
Interest received	41.60	(9.64)	41.60	(9.64)
Net cash flow from/(used in) investing activities (B)	(2,140.62)	(1,794.63)	(1,934.50)	(1,794.63)
CASH FLOWS FROM FINANCING ACTIVITIES :				
Proceeds from issuance of share capital	-	51.66	-	51.66
Proceeds from Securities Premium	-	2,453.85	-	2,453.85
Capital Reserve	-	-	(229.33)	-
Shares Warrants	-	-	-	-
Long-term borrowings net of repayment / Repayment of Long Term Borrowings	227.65	6.11	227.65	6.11
Proceeds from short-term borrowings	245.89	(645.65)	245.89	(645.65)
Interest paid	(19.10)	(37.75)	(19.10)	(37.75)
Dividends paid on equity shares	-	(122.17)	0.00	(122.17)
Tax on equity dividend paid	-	(24.87)	(0.00)	(24.87)
Net cash flow from/(used in) in financing activities (C)	454.44	1,681.18	225.12	1,681.18
Net increase/(decrease) in cash and cash equivalents (A + B + C)	(304.57)	(324.04)	(218.61)	(324.04)
Cash and cash equivalents at the beginning of the year	527.89	851.93	527.89	851.93
Cash and cash equivalents at the end of the year	223.32	527.89	309.28	527.89

For & on behalf of Board of Directors
Medicamen Biotech Limited



(Rahul Bishnoi)
Chairman

Place : Delhi
Dated : 30.06.2020

**TO THE BOARD OF DIRECTORS OF
Medicamen Biotech Limited**

1. We have audited the accompanying Statement of Consolidated Financial Results of Medicamen Biotech limited ("the Holding Company") and is Wholly Owned Subsidiary (OPAL Pharmaceuticals Pty Ltd) for the year ended March 31, 2020 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. In our opinion and to the best of our information and according to the explanations given to us, the statement;
 - gives a true and fair view in conformity with the applicable Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 (the Act) read with relevant rules issued there under, and other accounting principles generally accepted in India, of the Consolidated net profit after tax and other comprehensive income and other financial information of the Group for the year ended March 31, 2020.
 - Includes the annual financial results of its Wholly Owned Subsidiary (OPAL Pharmaceuticals Pty Ltd).

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SA) specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the ICAI) together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Act and the rules there under, we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis of our opinion.

Management's and those charged with Governance Responsibilities for the Statement

4. The Statement which is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true & fair view of the consolidated net profit/ loss after tax and other comprehensive income and other financial information of the Group in accordance with the accounting principles generally accepted in India, including IND AS prescribed under section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations including SEBI circular. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of provisions of the Act, the respective Board of Directors/ management of the Companies included in the Group covered under the Act, are responsible for maintenance of adequate accounting records in accordance with the

provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; section and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

5. In preparing the statement, the respective Board of Directors of the Companies included in the group are responsible for assessing the Group's ability to continue as a going concern, disclosing as applicable, matters related to going concern, and using the going concern basis of accounting unless the respective Board of Directors/ management either intends to liquidate the Group or to ease operations, or has no realistic alternative but to do so.
6. The respective Board of Directors/ management of the companies included in the Group are responsible for overseeing the Company's financial reporting process of the companies included in the Group.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that audit conducted in accordance with Standard on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of user taken on the basis of this statement.
8. As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are responsible for expressing our opinion on whether the Group have in place adequate internal financial controls system over financial reporting and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
 - Conclude on the appropriateness of the management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the



related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our opinion are based on the audit evidence obtained upto the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate that those charged with governance of the Holding Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
 10. We also provide that those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The Statement includes the financial results for the quarter ended March 31, 2020, being the balancing figures between the audited figures in respect of the full financial year and published audited year to date figures upto the third quarter of the current financial year, which were subject to audit by us.

For Rai Qimat & Associates
Chartered Accountants



(Membership Number: 080857)
UDIN:-20080857AAABL2353

Place: Gurgaon
Date: 30.06.2020

**TO THE BOARD OF DIRECTORS OF
Medicamen Biotech Limited**

1. We have audited the accompanying Statement of Standalone Financial Results of Medicamen Biotech Limited ("the Company") for the year ended March 31, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. In our opinion and to the best of our information and according to the explanations given to us, the statement gives a true and fair view in conformity with the applicable Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 (the Act) read with relevant rules issued there under, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended March 31, 2020.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SA) specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the ICAI) together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Act and the rules there under, we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's and those charged with Governance Responsibilities for the Statement


4. This statement has been prepared on the basis of the Standalone annual financial statements. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true & fair view of the net profit/ loss and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including IND AS prescribed under section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations including SEBI circular. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the statement, the Board of directors is responsible for assessing the Company's ability to continue as a going concern, disclosing as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors

either intends to liquidate the company or to ease operations, or has no realistic alternative but to do so.

6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that audit conducted in accordance with Standard on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of user taken on the basis of this statement.
8. As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are responsible for expressing our opinion on whether the company has in place adequate internal financial controls system over financial reporting and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
 - Conclude on the appropriateness of the management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our opinion are based on the audit evidence obtained upto the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue a going concern.
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate that those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



10. We also provide that those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The Statement includes the financial results for the quarter ended March 31, 2020, being the balancing figures between the audited figures in respect of the full financial year and published audited year to date figures upto the third quarter of the current financial year, which were subject to audit by us.

**For Rai Qimat & Associates
Chartered Accountants**



**(Membership Number: 080857)
UDIN:-20080857AAABL2353**

**Place: Gurgaon
Date: 30.06.2020**



MEDICAMEN BIOTECH LIMITED

INVESTOR PRESENTATION

June 2020


“Committed for affordable quality healthcare and aiming leadership through continual improvement and technology”

SAFE HARBOUR STATEMENT


This document contains certain forward looking statements with respect to the financial condition, results of operations and business of Medicamen Biotech Limited (“MBL”) and certain of the plans and objectives of MBL with respect to these items. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward looking statements. These factors include, but are not limited to, domestic and global economic and business conditions, the successful implementation of our strategy and our ability to realize the benefits of this strategy, our ability to develop and market new products, etc. As a result, MBL’s actual future results may differ materially from the plans, goals and expectations set forth in such forward looking statements. MBL does not undertake any obligation to update such forward looking statements to reflect events or circumstances after the date thereof.

OVERALL SNAPSHOT


Revenue (INR Lacs)




Gross Margin



EBITDA



PAT



All Amounts in INR Lacs

OVERALL SNAPSHOT (QUARTERLY)

INR Lacs	Q4, FY20*	CS	Q3, FY20	CS	Q4, FY19	CS
Revenue from Operations	2,352	100%	3,533	100%	2,408	100%
Other Income	110	5%	45	1%	7	0%
Total Income	2,462	105%	3,579	101%	2,415	100%
COGS	1,307	56%	2,236	63%	1,445	60%
Employee Benefit Expenses	247	10%	264	7%	213	9%
Finance Costs	-	0%	19	1%	20	1%
Depreciation	67	3%	64	2%	59	2%
Other Expenses	503	21%	490	14%	312	13%
Total Expenses	2,124	90%	3,073	87%	2,049	85%
Profit Before Tax	338	14%	506	14%	366	15%
Tax	89	4%	138	4%	125	5%
Profit After Tax	249	11%	368	10%	241	10%

Notes: Due to ban on exports and rise in the prices of API, the Company had to forgo sales order worth ~INR 1,800 lacs in Q4, FY20

* Consolidated numbers inclusive of Australian subsidiary

OVERALL SNAPSHOT (YEARLY)

INR Lacs	FY20	CS	FY19	CS
Revenue from Operations	12,550	100%	12,260	100%
Other Income	194	2%	366	3%
Total Income	12,744	102%	12,626	103%
COGS	7,892	63%	8,334	68%
Employee Benefit Expenses	952	8%	809	7%
Finance Costs	57	0%	94	1%
Depreciation	250	2%	221	2%
Other Expenses	1,795	14%	1,416	12%
Total Expenses	10,946	87%	10,874	89%
Profit Before Tax	1,798	14%	1,752	14%
Tax	469	4%	550	4%
Profit After Tax	1,329	11%	1,203	10%


KEY UPDATE - NEW ONCOLOGY FACILITY AT HARIDWAR



Propose to manufacture **20 products** of which **5 are top 10 global oncology drugs** of 2016



Focused markets include **European Union market, Latin America and Rest of the world**



Tablet, capsules, injectable, lyophilize in the following batch size:

- Tablets and capsules: 25 kg
- Injectable and lyophilizes: 50 litres

OVERVIEW


- **Business Area:**
 - *Developing, manufacturing and marketing of finished dosages across wide range of therapeutic domains*
 - *Contract Manufacturing / R&D based CMO service for customer products & new products*
- **Production site:** Three Manufacturing state of the art facilities
 - *2 General facility in Bhiwadi & Haridwar*
 - *1 Oncology facility in Haridwar, FDA USA compliant*
- Certified by WHO, ANVISA (Brazil), NAFDAC, MCAZ and DACA etc
- EU and PICS compliant facility

GLOBAL PRESENCE



ROBUST R&D CAPABILITIES


- ❑ World class Research & Development facility at **Bhiwadi** for development of Active Pharma Ingredients (API) and Intermediates along with Formulations R&D.
- ❑ **Approx. floor area of the R&D Unit. 6000 Sq. Ft approx**
- ❑ Backed by the team of highly professional and well-experienced team of researchers and scientist for development of new products.



Strength of R & D ~ 30 employees

FORMULATION CAPABILITIES


Machine Capability



Overall capacity utilisation of 60% in FY20

MANPOWER CAPABILITIES


Employee %



- Quality Assurance
- Production
- Quality Control
- R&D
- Store
- Purchase
- Others

More than adequate staff in QA/QC and Production to ensure quality deliveries

Technical Capability



Perfect blend of experience and technical know-how, promoting innovation and problem solving

NEW ONCOLOGY PLANT – HARIDWAR



R&D- BHIWADI



R&D- BHIWADI





MANUFACTURING – BHIWADI









HEALTHY CHAMBER
MILK-OK

12.3

HEALTHY CHAMBER
MILK-OK

Person in white lab coat, green hairnet, and green shoe covers.

F.G.WARE HOUSE

FINISHED GOODS
WAREHOUSE



Thank You!



MEDICAMEN BIOTECH LIMITED

Registered Office:

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi- 110019

Phone: 011-47589500 (30 Lines)

Fax: 011-26213081

E-mail: vk@medicamen.com

Website: www.medicamen.com